7926 related articles for article (PubMed ID: 30120041)
1. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
2. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
[TBL] [Abstract][Full Text] [Related]
3. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Preoperative Radiomic Approach to Evaluate Tumor-Infiltrating CD8
Liao H; Zhang Z; Chen J; Liao M; Xu L; Wu Z; Yuan K; Song B; Zeng Y
Ann Surg Oncol; 2019 Dec; 26(13):4537-4547. PubMed ID: 31520208
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
Duruisseaux M; Martínez-Cardús A; Calleja-Cervantes ME; Moran S; Castro de Moura M; Davalos V; Piñeyro D; Sanchez-Cespedes M; Girard N; Brevet M; Giroux-Leprieur E; Dumenil C; Pradotto M; Bironzo P; Capelletto E; Novello S; Cortot A; Copin MC; Karachaliou N; Gonzalez-Cao M; Peralta S; Montuenga LM; Gil-Bazo I; Baraibar I; Lozano MD; Varela M; Ruffinelli JC; Palmero R; Nadal E; Moran T; Perez L; Ramos I; Xiao Q; Fernandez AF; Fraga MF; Gut M; Gut I; Teixidó C; Vilariño N; Prat A; Reguart N; Benito A; Garrido P; Barragan I; Emile JF; Rosell R; Brambilla E; Esteller M
Lancet Respir Med; 2018 Oct; 6(10):771-781. PubMed ID: 30100403
[TBL] [Abstract][Full Text] [Related]
7. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
[TBL] [Abstract][Full Text] [Related]
8. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
9. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
10. Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma.
Park KJ; Lee JL; Yoon SK; Heo C; Park BW; Kim JK
Eur Radiol; 2020 Oct; 30(10):5392-5403. PubMed ID: 32394281
[TBL] [Abstract][Full Text] [Related]
11. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
13. Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
Ogura A; Akiyoshi T; Yamamoto N; Kawachi H; Ishikawa Y; Mori S; Oba K; Nagino M; Fukunaga Y; Ueno M
Eur J Cancer; 2018 Mar; 91():11-20. PubMed ID: 29328976
[TBL] [Abstract][Full Text] [Related]
14. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.
Paré L; Pascual T; Seguí E; Teixidó C; Gonzalez-Cao M; Galván P; Rodríguez A; González B; Cuatrecasas M; Pineda E; Torné A; Crespo G; Martin-Algarra S; Pérez-Ruiz E; Reig Ò; Viladot M; Font C; Adamo B; Vidal M; Gaba L; Muñoz M; Victoria I; Ruiz G; Viñolas N; Mellado B; Maurel J; Garcia-Corbacho J; Molina-Vila MÁ; Juan M; Llovet JM; Reguart N; Arance A; Prat A
Ann Oncol; 2018 Oct; 29(10):2121-2128. PubMed ID: 30165419
[TBL] [Abstract][Full Text] [Related]
15. A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC.
Chen M; Lu H; Copley SJ; Han Y; Logan A; Viola P; Cortellini A; Pinato DJ; Power D; Aboagye EO
J Thorac Oncol; 2023 Jun; 18(6):718-730. PubMed ID: 36773776
[TBL] [Abstract][Full Text] [Related]
16. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
17. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells.
Sun R; Sundahl N; Hecht M; Putz F; Lancia A; Rouyar A; Milic M; Carré A; Battistella E; Alvarez Andres E; Niyoteka S; Romano E; Louvel G; Durand-Labrunie J; Bockel S; Bahleda R; Robert C; Boutros C; Vakalopoulou M; Paragios N; Frey B; Soria JC; Massard C; Ferté C; Fietkau R; Ost P; Gaipl U; Deutsch E
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188037
[TBL] [Abstract][Full Text] [Related]
18. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]